Exelixis (EXEL) Total Non-Current Liabilities (2010 - 2026)
Exelixis (EXEL) recorded quarterly Total Non-Current Liabilities of $540.5 million in Q2 2026, down 6.6% quarter-over-quarter from $578.7 million in Q1 2026, and down 7.8% on a YoY basis from $586.2 million in Q2 2025.
Exelixis (EXEL) Total Non-Current Liabilities (2010 - 2026) Analysis & Trends
Exelixis' Total Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $540.5 million for Q2 2026.
- In Q2 2026, Total Non-Current Liabilities fell 7.8% year-over-year to $540.5 million; the TTM figure through Apr 2026 stood at $540.5 million (down 7.8% YoY), while the FY2026 annual figure was $578.7 million, down 2.68% from the prior year.
- Total Non-Current Liabilities was $540.5 million for Q2 2026 at Exelixis, down from $578.7 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $594.6 million in Q1 2025 to a low of $347.8 million in Q2 2022.
- Historically, Total Non-Current Liabilities has averaged $534.7 million across 5 years, with a median of $543.7 million in 2024.
- The sharpest annual moves came in 2023 and 2026: Total Non-Current Liabilities jumped 49.78% in 2023, then fell 7.8% in 2026.
- A 5-year view of Total Non-Current Liabilities shows it stood at $514.5 million in 2022, then rose by 13.54% to $584.2 million in 2023, then rose by 0.78% to $588.8 million in 2024, then retreated by 6.55% to $550.2 million in 2025, then retreated by 1.77% to $540.5 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $540.5 million (Q2 2026), $578.7 million (Q1 2026), and $550.2 million (Q4 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | 42,980.09 |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | 64.76 Mn |
| 10 | Exelixis | 13.71 Bn | 12.93 Bn | 590.86 Mn | 540.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 540.52 Mn |
| Jan 2, 2026 | 578.68 Mn |
| Oct 3, 2025 | 550.24 Mn |
| Jul 4, 2025 | 515.95 Mn |
| Apr 4, 2025 | 586.23 Mn |
| Jan 3, 2025 | 594.59 Mn |
| Sep 27, 2024 | 588.79 Mn |
| Jun 28, 2024 | 543.72 Mn |
| Mar 29, 2024 | 574.48 Mn |
| Dec 29, 2023 | 584.22 Mn |
| Sep 29, 2023 | 567.67 Mn |
| Jun 30, 2023 | 541.04 Mn |
| Mar 31, 2023 | 520.84 Mn |
| Dec 30, 2022 | 514.53 Mn |
| Sep 30, 2022 | 468.06 Mn |
| Jul 1, 2022 | 472.75 Mn |
| Apr 1, 2022 | 347.75 Mn |
| Dec 31, 2021 | 397.60 Mn |
| Oct 1, 2021 | 331.20 Mn |
| Jul 2, 2021 | 317.13 Mn |